| scholarly article | Q13442814 |
| P2093 | author name string | Ronald A Ghossein | |
| R Michael Tuttle | |||
| David G Pfister | |||
| Heiko Schöder | |||
| Matthew G Fury | |||
| Sofia Haque | |||
| Ashok R Shaha | |||
| Eric J Sherman | |||
| Donna Lisa | |||
| Yungpo Bernard Su | |||
| Ashima Lyall | |||
| P2860 | cites work | Cancer statistics, 2013 | Q27860762 |
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms | Q33341474 | ||
| A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. | Q33345375 | ||
| Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma | Q33381498 | ||
| FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. | Q34472558 | ||
| Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation | Q34714310 | ||
| Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. | Q35023367 | ||
| Treatment of thyroid cancer with histone deacetylase inhibitors and peroxisome proliferator-activated receptor-gamma agonists | Q36200247 | ||
| Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study | Q36877022 | ||
| Phase II trial of sorafenib in advanced thyroid cancer | Q37121708 | ||
| Phase II trial of sorafenib in metastatic thyroid cancer | Q37158278 | ||
| Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. | Q40211424 | ||
| Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo | Q40227787 | ||
| Novel histone deacetylase inhibitors in the treatment of thyroid cancer | Q40422202 | ||
| Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin | Q40587596 | ||
| Histone deacetylase inhibitors promote apoptosis and differential cell cycle arrest in anaplastic thyroid cancer cells | Q43605245 | ||
| Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells | Q43666601 | ||
| Long-Term Results of Treatment of 283 Patients with Lung and Bone Metastases from Differentiated Thyroid Carcinoma | Q63406409 | ||
| Thyroid carcinoma | Q72991392 | ||
| P433 | issue | 5 | |
| P921 | main subject | iodine | Q1103 |
| iodine in medicine | Q28196266 | ||
| P304 | page(s) | 593-599 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Thyroid | Q15709940 |
| P1476 | title | Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma | |
| P478 | volume | 23 |
| Q47160397 | A phase II trial of valproic acid in patients with advanced, radioiodine-resistant thyroid cancers of follicular cell origin |
| Q38217744 | Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets |
| Q38823954 | Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer |
| Q42101746 | Epigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer |
| Q38459836 | Epigenetic therapy for solid tumors: from bench science to clinical trials |
| Q38222938 | External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer |
| Q38128097 | Genetics and epigenetics of sporadic thyroid cancer |
| Q37554758 | Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype. |
| Q42089195 | HOTAIR is a promising novel biomarker in patients with thyroid cancer |
| Q92003943 | Key actors in cancer therapy: epigenetic modifiers |
| Q64228886 | MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring : An Study |
| Q54258517 | Melatonin suppresses thyroid cancer growth and overcomes radioresistance via inhibition of p65 phosphorylation and induction of ROS. |
| Q35690173 | Modulation of sodium iodide symporter in thyroid cancer |
| Q26774734 | Molecular Targeted Therapies of Aggressive Thyroid Cancer |
| Q87331632 | Moving toward a better understanding of radioiodine action |
| Q35381593 | New therapies for dedifferentiated papillary thyroid cancer |
| Q36602187 | Novel Approaches to Thyroid Cancer Treatment and Response Assessment |
| Q38737667 | PDGFRα Regulates Follicular Cell Differentiation Driving Treatment Resistance and Disease Recurrence in Papillary Thyroid Cancer. |
| Q37667088 | Phase I trial of a new schedule of romidepsin in patients with advanced cancers |
| Q28396209 | Phenethyl isothiocyanate and paclitaxel synergistically enhanced apoptosis and alpha-tubulin hyperacetylation in breast cancer cells |
| Q90360173 | Radioactive Iodine-Refractory Differentiated Thyroid Cancer and Redifferentiation Therapy |
| Q46073511 | Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy |
| Q37123127 | SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model |
| Q90387005 | Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine |
| Q35821728 | Targeting Histone Deacetylases in Diseases: Where Are We? |
| Q35246513 | Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma |
| Q38865611 | The Treatment of Advanced Thyroid Cancer in the Age of Novel Targeted Therapies |
| Q36379340 | Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome |
Search more.